Authors
Ethan J Anderson, Giulio Vistoli, Lalage A Katunga, Katsuhiko Funai, Luca Regazzoni, T Blake Monroe, Ettore Gilardoni, Luca Cannizzaro, Mara Colzani, Danilo De Maddis, Giuseppe Rossoni, Renato Canevotti, Stefania Gagliardi, Marina Carini, Giancarlo Aldini
Publication date
2018/12/3
Journal
The Journal of clinical investigation
Volume
128
Issue
12
Pages
5280-5293
Publisher
American Society for Clinical Investigation
Description
Sugar- and lipid-derived aldehydes are reactive carbonyl species (RCS) frequently used as surrogate markers of oxidative stress in obesity. A pathogenic role for RCS in metabolic diseases of obesity remains controversial, however, partly because of their highly diffuse and broad reactivity and the lack of specific RCS-scavenging therapies. Naturally occurring histidine dipeptides (e.g., anserine and carnosine) show RCS reactivity, but their therapeutic potential in humans is limited by serum carnosinases. Here, we present the rational design, characterization, and pharmacological evaluation of carnosinol, i.e., (2S)-2-(3-amino propanoylamino)-3-(1H-imidazol-5-yl)propanol, a derivative of carnosine with high oral bioavailability that is resistant to carnosinases. Carnosinol displayed a suitable ADMET (absorption, distribution, metabolism, excretion, and toxicity) profile and was determined to have the greatest potency …
Total citations
2018201920202021202220232024113222211198
Scholar articles
EJ Anderson, G Vistoli, LA Katunga, K Funai… - The Journal of clinical investigation, 2018